Nucleic acids encoding human anti-NGF neutralizing antibodies as selective NGF pathway inhibitors
US7795413B2 · kind B2 · utility
33Cited by
12References
9Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jun 22, 2007 |
| Grant date | Sep 14, 2010 |
| Priority date | — |
| Expiry date | Jun 22, 2027 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2800/2842
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
This invention provides antibodies that interact with or bind to human nerve growth factor (NGF) and neutralize the function of NGF thereby. The invention also provides pharmaceutical compositions of said antibodies and methods for neutralizing NGF function, and particularly for treating NGF-related disorders (e.g., chronic pain) by administering a pharmaceutically effective amount of anti-NGF antibodies. Methods of detecting the amount of NGF in a sample using anti-NGF antibodies are also provided.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.